Eurofins Successfully Prices EUR 400m New Hybrid Bond
2017年11月7日 - 2:43AM
ビジネスワイヤ(英語)
This document contains inside information
for the purpose of Regulation (EU) 596/2014 of the European
Parliament and of the Council of 16 April 2014 on market
abuse
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (ERF FP, unrated), a global leader in
bioanalytical testing, announces that it has successfully raised
EUR 400m in its latest Euro hybrid bond public issuance to further
strengthen its balance sheet. The transaction was well received and
more than 8x times over-subscribed.
This new series of bonds has no specified maturity, and is
accounted for as 100% equity according to international financial
reporting standards (IFRS). It is callable at par by Eurofins on
the 8th year (Perp NC8, first call date in November 2025) and is
structured for optimum equity qualification by rating agencies
should the company opt for a credit rating in the next 3 years. It
will bear a fixed annual coupon of 3.25% for the first 8 years, the
lowest ever hybrid bond coupon achieved by Eurofins.
Eurofins intends to use the proceeds of this new issuance for
general corporate purposes, including the funding of growth
opportunities beyond its EUR 4bn revenues objectives for 2019.
Comment from Dr. Gilles Martin, Eurofins CEO: “The
successful issuance of our new EUR 400m hybrid capital instrument,
in combination with the successful EUR 299m equity raise announced
on October 31st 2017, have significantly strengthened Eurofins’
balance sheet and will allow the Group to continue to respond
swiftly to attractive M&A opportunities above and beyond those
contemplated as part of its EUR 4bn revenue objective for
2019.”
BNP Paribas, Bank of America Merrill Lynch, HSBC and UniCredit
acted as Global Coordinators and together with BayernLB and Danske
Bank, as active Joint Lead Managers for the transaction. Settlement
date is on the 13th of November, 2017, and the first call date for
the instrument is on the 13th of November, 2025.
The bonds will be listed from their issue date (13th November
2017) on the regulated market of the Luxembourg stock exchange
(ISIN XS1716945586). The bonds are not registered under the US
Securities Act of 1933 as amended (the “Securities Act”), and may
not be offered or sold in (i) the United States (as such term is
defined in Regulation S under the Securities Act) unless registered
under the Securities Act or pursuant to an exemption from such
registration nor (ii) in any other jurisdiction where it is
unlawful to do so.
For more information, please visit
www.eurofins.com
Notes for the editor:Eurofins – a global leader in
bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 30,000
staff in 400 laboratories across 41 countries, Eurofins offers a
portfolio of over 150,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:This press release contains
forward-looking statements and estimates that involve risks and
uncertainties. The forward-looking statements and estimates
contained herein represent the judgment of Eurofins Scientific’s
management as of the date of this release. These forward-looking
statements are not guarantees for future performance, and the
forward-looking events discussed in this release may not occur.
Eurofins Scientific disclaims any intent or obligation to update
any of these forward-looking statements and estimates. All
statements and estimates are made based on the information
available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171106006126/en/
Investor RelationsEurofins Scientific SEPhone: +32-2-769
7383E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 6 2024 まで 7 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 7 2023 まで 7 2024